Meibocyte differentiation and renewal: Insights into novel mechanisms of meibomian gland dysfunction (MGD)

CLINICAL SCIENCE A New System, the LipiFlow, for the Treatment of Meibomian Gland Dysfunction (MGD)

Methods: This was a non-significant risk, prospective, open-label, randomized, crossover multicenter clinical trial. One hundred thirtynine subjects were randomized between LipiFlow (n=69) and WC control (n=70). Subjects in the LipiFlow group received a 12-minute LipiFlow treatment and were reexamined at 1 day, 2 weeks and 4 weeks. Control subjects received a 5-minute iHeat treatment with instr...

Meibomian gland dysfunction

Meibomian gland dysfunction.

Blepharitis is probably the most common disease entity seen in the general ophthalmologist's office. A significant proportion of these cases are secondary to meibomian gland disease. This review outlines our knowledge of the histopathology, lipid abnormalities and role of microorganisms in meibomian gland dysfunction. We will also review the physiology of meibomian gland secretion and present m...

Meibomian Gland Dysfunction and Hypercholesterolemia

High cholesterol is a known risk factor for ischemic heart, cerebrovascular, and peripheral vascular disease. Previous studies have postulated that hypercholesterolemia (defined as total cholesterol of at least 200 mg/dL) also plays a role in the development of meibomian gland dysfunction (MGD). In this observational, case-control study, Pinna et al. investigated the correlation between MGD and...

Effects of age and dysfunction on human meibomian glands.

OBJECTIVE To identify age-related changes in human meibomian glands that may be associated with meibomian gland dysfunction (MGD). METHODS Excess eyelid tissue from 36 patients (age range, 18-95 years, 19 female, 17 male) who underwent canthoplasty procedures were used. Dermatologic history, age, and presence of MGD were recorded. Samples were frozen, sectioned, and stained with specific anti...